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Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) have become a rising threat
to public health. There is an urgent need for development of promising new therapeutic agents
against drug resistant bacteria like S. aureus. This report discusses purification and characterization
of proteins from Indian Russell’s viper snake venom. Novel 15-kDa proteins called ‘‘Viperatoxin”
(VipTx-I and VipTx-II) were extracted from the whole venom and evaluated using in vitro antimicro-
bial experiments. The N-terminal amino acid sequence of ‘‘Viperatoxin” showed high sequence
homology to daboiatoxin isolated from the same venom and also matched phospholipase A2
(PLA2) enzymes isolated from other snake venoms. In an in vitro plate assay, VipTx-II but not
VipTx-I showed strong antimicrobial effects against S. aureus and Burkholderia pseudomallei
(KHW & TES), Proteus vulgaris and P. mirabilis. The VipTx-II was further tested by a broth-
dilution assay at 100–3.125 lg/ml concentrations. The most potent bactericidal effect was found
at the lowest dilutions (MICs of 6.25 lg/ml) against B. pseudomallei, S. aureus and P. vulgaris
(MICs of 12.25 lg/ml). Electron microscopic investigation revealed that the protein-induced bacteri-
cidal potency was closely associated with pore formation andmembrane damage, even at the lowest
concentrations (<20 lg/ml). The toxin caused a low level of cytotoxic effects as observed in human
(THP-1) cells at higher concentrations. Molecular weight determinations of VipTx-II by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis showed one major, along with a few minor
bands. The results indicate that VipTx-II plays a significant role in bactericidal and membrane dam-
aging effects in vitro. Non-cytotoxic properties on human cells highlight it as a promising candidate
for further evaluation of antimicrobial potential in vivo.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2; MTXs,
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Infections caused by methicillin-resistant Staphylococcus aureus
(MRSA) have become a very important threat to public health [1]. It
can cause severe disease, including necrotizing fasciitis, sepsis,
endocarditis and pneumonia [2]. The Gram-negative bacterium
Burkholderia pseudomallei causes not only human melioidosis [3]
but also community-acquired bacteraemic pneumonia [4], sep-
ticemias and also high mortality due to septic shock [5]. The pres-
ence of septicaemia (44%) and major organ failure (48%) results in
death as well as relapse in patients with inappropriate treatment
[6]. B. pseudomallei are intrinsically resistant to many antimicrobial
agents including first and second generations of cephalosporins,
penicillin, macrolides, colistin, rifamycins and aminoglycosides
[7]. The above drugs cause serious side effects such as nephrotox-
icity and neurotoxicity. Therefore, there is an urgent need for the
development of promising new therapeutic agents against drug-
resistant bacteria.
Antimicrobial proteins and peptides are produced by all forms
of living organisms and represent a novel class of antibiotics to
treat infectious diseases [8]. Snake venoms are an extremely rich
source of pharmacologically-active proteins with considerable
clinical potential [9,10]. Snake venoms from Viperidae species pos-
sess significant bactericidal inhibition [11]. Previous studies show
that various venom proteins possess significant antimicrobial
activity [12,13].
Several types of secreted phospholipase A2 (sPLA2) reportedly
exert potent bactericidal actions dependent upon their enzymatic
activities [14]. sPLA2s have been implicated in lipid digestion to
enhance host defence mechanisms that include antibacterial prop-
erties [15]. Many studies have demonstrated that the type-IIA
sPLA2 is an endogenous antibiotic-like protein that kills bacteria
[16]. The acidic PLA2 from Porthidium nasutum snake venom has
antibacterial activity [17]. PLA2 homologues present in snake ven-
oms, known as Lys49 PLA2s [18], also have bactericidal activity.
Myotoxic PLA2 enzymes are also known to induce bactericidal
activity against Escherichia coli and S. aureus [19,20]. The bacterici-
dal effect of PLA2 isolated from Bothrops snake venoms is report-
edly due to its catalytic activity [21] but according to Lomonte
et al. [19], the catalytically inactive myotoxic Lys49-PLA2 can also
induce a bactericidal effect. PLA2 myotoxins purified from crotali-
dae snake venoms, including both Lys49 and Asp49-type isoforms,
are bactericidal and thus indicate a common mechanism of action
for the IIA PLA2 protein family. There are not only bactericidal
properties of short cationic peptides derived from a snake venom
Lys49-PLA2 [20,22], but also anti-HIV [23] and anti-fungal activity
of a PLA2-derived synthetic peptide variant against Candida
albicans [24]. A group of antimicrobial peptides derived from the
C-terminal sequence 115–129 of myotoxin II and its triple
Tyr–Trp substituted peptide p115-W3, have been reported previ-
ously [22]. More tryptophan substitutions increased microbicidal
potency against Gram-negative and Gram-positive bacteria [25].
Another study reported that the myotoxins (MTXs) of B. brazili
and cationic synthetic peptides derived from the C-terminal region
(115–129) can display antimicrobial effects against E. coli and
C. albicans [26]. Thus, an enzymatically-independent bactericidal
effect of PLA2 protein has also been demonstrated for a specific
membrane-damaging protein site [27]. Another study shows that
this peptide interacts with lipopolysaccharide (LPS) and lipid A
from different Gram-negative bacteria, or with lipoteichoic acid
from S. aureus, and relies on a membrane-permeabilizing mecha-
nism to exert its bactericidal effects [27].
Indian Russell’s viper snake venom (Daboia russelli russelli)
contains complex mixtures of many distinct proteins [28], ions,
biogenic amines, polyamines, polypeptides, neurotoxins, cytolyticpeptides, enzymes, thrombin-like proteinase [29], L-amino acid
oxidase [30], procoagulant enzymes (factor X) [31], V activators
[32], haemorrhagins [33], basic PLA2 and acidic PLA2 [34]. This
viper venom is an enormous source of proteins/peptides that have
not been fully explored for antimicrobial properties. In the present
study, we purified two novel proteins (VipTx-I and VipTx-II) and
determined their homogeneity by sodium dodecylsulphate poly-
acrylamide gel electrophoresis (SDS–PAGE), Matrix Assisted Laser
Desorption/ionization-Time of Flight mass spectrometry (MALDI
TOF/MS), N-terminal amino acid sequence, and antimicrobial
activity with the latter mechanism of action determined by elec-
tron microscopy.
2. Experimental procedures
2.1. Chemicals
Chemicals and solvents were obtained from Fluka Chemie
GmbH (Deisenhofen, Germany) and Merck (Darmstadt, Germany).
Electrophoresis materials such as bromophenol blue,
2-mercaptoethanol, glycerol, sodium dodecylsulphate (SDS),
Coomassie Brilliant Blue R-250, 30% acrylamide/bisacrylamide,
ammonium persulphate and N,N,N,N-tetramethylethylenediamine
(TEMED) were from Bio-Rad (Hercules, CA, USA). Dye reagent for
protein assay (Bio-Rad) and all other reagents were from Sigma
(St Louis, MO, USA).
2.2. Extraction of venom
Lyophilized venom of D. russelli russelli (Indian Russell’s viper)
was purchased from commercial sources (Venom Supplies Pte
Ltd, Tanunda, South Australia). The venom samples were collected
in a sterile manner under strict laboratory conditions, and were
transferred to microcentrifuge tubes, immediately frozen and
lyophilized. The dried venomwas normally packed and stored dark
at 20 C.
2.3. Purification of protein
Lyophilized whole crude venom (500 mg) of D. russelli russelli
was dissolved with 10 ml of 50 mM (pH 7.4) Tris-hydrochloric acid
(Tris–HCl) buffer. The suspension was centrifuged at 500 g at 4 C
for 15 min and filtered through a 0.22 lm syringe filter (Nalge
Nunc International, Rochester, NY, USA) to remove any colloidal
or particulate material. Aliquots of the yellowish clear supernatant
were loaded on a Superdex G-75 column (1.6  40 cm; Amersham
Pharmacia (GE Healthcare, Upsala, Sweden) previously equili-
brated with the same buffer (50 mM Tris–HCl, pH 7.4). Fractions
(2 ml) were collected at a flow rate of 15 ml/h. The absorbance of
all fractions was monitored at 280 nm. Eight fractions (RV1-RV8)
were collected from the single pool of venom fractionated by a
G-75 gel-filtration column and aliquots taken for testing
antibacterial and PLA2 activities, as well as protein measurement.
The fraction (RV5) with highest antibacterial and PLA2 activities
was further separated by using a C18 sepharose column
(250  4.6 mm, 300 Å, 5 lm) with reverse-phase (RP)-high perfor-
mance liquid chromatography (RP-HPLC) and resolved into four
protein fractions (RV-F1, RV-F2, RV-F3, RV-F4) monitored at
254 nm. Of which, the active fraction RV-F4 was further purified
by C8 sepharose column (Jupitor Phenomenex, Torrance, CA,
USA) in 0.1% trifluoroacetic acid (TFA) in water eluted with a linear
gradient of 80% acetonitrile (ACN) in 0.1% TFA at 215 nm. Pure
protein fractions (VipTx-I and VipTx-II) were collected separately
with a FC905 B fraction collector (0.5 ml per min) and designated
as ‘‘viperatoxin”.
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Protein concentrations of samples were determined by the
method of Bradford [35], as modified by BioRad Laboratories
(San Diego, CA, USA). Purified PLA2 samples were prepared at
4.0 mg/ml concentrations, using bovine gamma-globulin for the
standard curve.
2.5. Protein analysis by SDS–PAGE
The purity of isolated VipTx-I and VipTx-II was verified by
SDS–PAGE (4.5 stacking gel/14% separating gels – Tris-glycine
running buffer) according to Laemmli, [36]. The fractions were
diluted 1:1 with sample buffer (0.12 M Tris–HCl, pH 6.8 containing
2% SDS, 5% 2-mercapethanol, 10% glycerol, 0.02% bromophenol
blue) and heated for 5 min in a boiling water bath. Electrophoresis
was carried out at a constant current 20 mA for 2.5 h. The gel was
fixed with 5% acetic acid overnight and stained for 2 h in 0.1%
Coomassie Brilliant Blue R-250 in 5% acetic acid. Destaining was
carried out in a solution containing 35% methanol and 7% acetic
acid until the background became clear. The molecular weights
of protein bands were determined using Bio-Rad SDS molecular
weight markers.
2.6. Determination of molecular mass
Molecular weight analyses were performed primarily using a
Perspective Biosystem matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF/MS) voyager-DE mass spec-
trometer (Framingham, MA), operated in delayed extraction mode.
The enzymes (0.1 ll applied on a cleanmatrix plate) were analyzed
using a saturated solution of a-cyano-4-hydroxycinnamic acid in
acetone containing 1% TFA (Sigma, St. Louis, MO, USA). The pro-
teins were selected in the mass range of 10,000–50,000 Da. Spectra
were calibrated using calibration mixture 2 of the sequazyme
peptide mass standards kit (AB SCIEX). MS-Fit was used for
searches in the National Center for Biotechnological Information
(NCBI) database. MALDI-TOF mass spectrometry was used for
molecular weight determination.
2.7. Analysis of sequencing
Suitable enzymes were subject to N-terminal sequencing by
Edman degradation using an Applied Biosystems 494 pulsed
liquid-phase sequencer, equipped with an on-line 120 A PTH-
amino acid analyzer at the National University of Singapore
(NUS), Singapore. The resulting amino acid (AA) sequences were
submitted to Basic Local Alignment Search Tool (BLAST) for
sequence similarity search (http://web.expasy.org/cgi-bin/blast/
blast.pl) by using the ExPASy World Wide Web (WWW) molecular
biology server of the Swiss Institute of Bioinformatics (SIB). When
the N-terminal sequences of VipTx-I and VipTx-II were blasted for
sequence similarity. The VipTx-I and VipTx-II masses were differ-
ent from that reported for D. russelli russelli (Indian Russell’s viper)
in an earlier report [34].
2.8. PLA2 enzyme activity (PLA2)
The Cayman chemical secretory PLA2 (sPLA2) assay kit was used
for measuring PLA2. The PLA2 enzyme activity is also converted to
lmoles of fatty acid released per min per mg phospholipase by
decreased absorbance produced by a known amount of acid. A
decrease in absorbance of 0.1 was obtained with 0.025 lmoles of
HCl in the reaction mixture [37].2.9. Antimicrobial assay
Clinical isolates of Gram-negative bacteria E. coli (ATCC 25922),
Enterobacter aerogenes, Proteus vulgaris (ATCC27968), Proteus mir-
abilis (ATCC35491), Pseudomonas aeruginosa (ATCC27853), B. pseu-
domallei (TES21), B. pseudomallei (KHW22) and the Gram-positive
bacterium S. aureus (ATCC 29213) were obtained from the
Department of Microbiology, Yong Loo Lin School of Medicine,
NUS, Singapore. The following antimicrobial agents: Streptomycin
(30 lg/disc), Chloramphenicol (30 lg/disc), Ceftazidime (30 lg/disc),
Penicillin (10 units) and Vancomycin (10 units) (Becton Dickinson
Labware, USA) were included as positive controls. Blank discs with
sterile double-distilled water served as a negative control [38].
Mueller Hinton (MH) and Tryptic Soya (TS) agar medium was pur-
chased from Oxoids, UK. The bacterial cultures were spread and
allowed to grow overnight at 37 C on 20 ml MH or TS agar (pH
7.4) plates (100 mm diameter) prior to storage at 4 C. Antimicro-
bial susceptibility was tested according to the method of Bauer
et al [39]. Gram-negative bacteria (E. coli, E. aerogenes, P. vulgaris,
P. mirabilis, P. aeruginosa) and Gram-positive bacteria (S. aureus)
were grown in MH broth, while B. pseudomallei (TES and KHW)
were grown in TS broth (OD600 1.0) which corresponds to
1.5  105–3.2  106 colony forming units (CFU/ml). Bacteria were
incubated with VipTx-I and VipTx-II at 100 lg/ml concentrations
on MH and TS solid agar plates incubated for 24 h at 37 C.
Bacterial inhibition zones were measured as millimeters in
diameter (inhibitory zones).
2.9.1. Minimum inhibitory concentrations (MICs)
Preparation of bacterial inoculums from frozen suspensions
were sub-cultured onto MH and TS agar plates and passaged twice
prior to susceptibility testing. The bacteria were grown in MH
broth for 5–7 h (exponential phase) before adjusting concentration
to a 0.5 McFarland turbidity standard. The adjusted bacterial cul-
tures were diluted to approximately 3.2  106 CFU/ml [17]. MICs
were determined by the broth micro-dilution techniques [40], for
which serial dilutions of VipTx-I and VipTx-II were prepared at
100, 50, 25, 12.5, 6.125, 3.078 lg/ml in 96-well microtiter trays
with appropriate broths (MH & TS), whereas multi-drug resistant
B. pseudomallei (TES & KHW) was tested at 3.078–100 lg/ml con-
centrations in TS broth. Three replicates were used for each dilu-
tion series that included control wells containing bacteria
without VipTx-I or VipTx-II. A 200 ll aliquot of the 106 CFU/ml
was added to each well (96-well plates) with 50 ll of VipTx-II.
The culture trays were incubated at 37 C for 24 h, the inhibition
of bacterial growth was determined by measuring the absorbance
at 600 nm (Sunrise Precision Microplate reader, Tecan Group Ltd,
Mannedorf, Switzerland). The MICs were taken as the lowest
concentration of VipTx-I or VipTx-II that inhibited visible
growth. The results given are mean values of three independent
determinations. After MIC measurement, each dilution of proteins
treated with bacterial samples (20 ll) were spread on to MH and
TS agar plates and incubated at 37 C for 24 h. Minimum bacterici-
dal concentrations (MBCs) were assayed at 100–3.125 lg/ml
concentrations.
2.9.2. Scanning electron microscopy (SEM)
The structural changes induced by VipTx-II (100-3.078 lg/ml)
on S. aureus, B. pseudomallei (KHW & TES), E. aerogenes, P. vulgaris,
and P. mirabilis were studied using SEM as described earlier [41].
Each protein sample (50 ll) contained (bacteria) pre-incubated
together for 30 min at 37 C. The control received equivalent
volumes of MH broth containing bacteria. After removing a small
portion of these samples for CFU/ml measurements, the remainder
was centrifuged for 10 min at 2800g. Pellets were resuspended
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phosphate buffer (pH 7.4) for 1 h. Immediately following addition
of fixative solution, the sample tubes were mixed by gently invert-
ing them up and down for several minutes to prevent clumping of
cells. The cells were post-fixed for an additional hour with 1%
osmium tetroxide (OsO4) and washed thrice in PBS. Samples
(1 ll) were pipetted onto a sterile cover glass coated with poly-L
lysine and left for 20–30 min. The section was dehydrated by a
series of alcohol baths (25%, 50%, 75%, 90% 100%). The samples
were transferred from 100% ethanol to a critical point dryer
(Balzers CPD-030, Bal-Tec AG, Vaduz, Liechtenstein), and dried
using liquid carbon dioxide. The samples were mounted on
aluminum specimen supports with carbon adhesive tabs, and
coated with a 10–15 nm thickness of gold using a sputter coater
SC D005 (Bal-Tec, EM Technology and Application, Liechtenstein).
Samples were examined with a Philips XL 30 FEG SEM (Electron
Microscopy, Japan) using an accelerating voltage of 5–10 kV.
2.9.3. Transmission electron microscopy (TEM)
The structural changes induced by VipTx-II on S. aureus and
B. pseudomallei (KHW) were studied using TEM as described earlier
[42]. Bacterial cells suspended in 10 mM phosphate buffer (pH 7.4)
treated with VipTx-II (6.25 lg/ml) were fixed with an equal
volume of 2.5% glutaraldehyde in 10 mM phosphate buffer, pH
7.4. The fixed samples were stored overnight at 4 C in fixative
solution. The suspended cells were rinsed with 10 mM phosphate
buffer, and dehydrated through a graded series of ethanol
(25–100%). During the entire filtration, rinsing, and dehydration
process, cells were covered with fluid to prevent air drying. The
samples were transferred from 100% ethanol in to a critical point
dryer, and dried using carbon dioxide. The samples were mounted
on aluminum specimen supports with carbon adhesive tabs, and
coated with gold-palladium metal (60:40 alloy and 15 nm thick-
ness) using a Hummer X sputter coater (Bal-Tec, EM Technology
and Application, Liechtenstein). Samples were examined with a
(JEF 2220) TEM using an accelerating voltage of 5–10 kV.
2.9.4. Cell proliferation and cytotoxicity (MTT based) assay
The human macrophage cells (THP-1) were obtained from
ATCC, (Virginia, USA). Sterile Dulbecco’s Modified Eagle’s Medium
(DMEM), Fetal Bovine Serum (FBS), and 10 mM HEPES were
purchased from the National University Medical Institute (NUMI),
Singapore. All chemicals were of analytical and cell culture grade.
THP-1 cells were cultured in 72 cm2 flasks at a density of
107 cells/ml in DMEM culture medium supplemented with 10%
FBS, and 1 ml of HEPES. The cells adhered to the flask bottom
overnight at 37 C in a humidified atmosphere of 5% CO2 and 95%
air. The culture medium was changed four times a week. To ana-
lyze the initial events of VipTx-I and VipTx-II upon cell viability,
the proteins were applied to THP-1 cells at different concentrations
(10,000–39 lg/ml) with varied time intervals (24 and 48 h),
tetrazolium dye added and incubated for 30 min. Cell proliferation
was assessed by measuring optical density (OD) using an ELISA
plate reader at 490 nm. All assays were performed in triplicates
and repeated thrice.
2.9.5. Cytolytic assay by lactate dehydrogenase (LDH)
Cytolytic effects of proteins on human acute monocytic leuke-
mia cells were evaluated by measuring the release of LDH enzyme
using a cytotoxicity detection kit (Roche Mannheim, Germany).
Proteins (VipTx-I and VipTx-II) were added to THP-1 cells
(106 cells/well) cultured on 96-well plates in DMEM medium
(NUMI, Singapore) supplemented with 10% (vol/vol) FBS. The pro-
teins (10,000–39 lg/ml) were added and further incubated with
cells for 24 and 48 h. A 200 ll aliquot of the centrifuged super-
natant obtained from each well was used for the quantificationof cell death and lysis, based on the measurement of LDH activity
released from the cytosol of damaged cells into the supernatant.
The assay was performed in triplicate.
2.9.6. Statistical analysis
The results (mean ± S.D., n = 5) were statistically analyzed by
one way ANOVA with repeated measures used to analyze factors
influencing the size of the growth inhibition zones. The level of
statistical significance was at ⁄P < 0.01 and ⁄⁄P < 0.05 etc.
3. Results
3.1. Purification and characterization of protein
Viperatoxin was purified from the venom of Russell’s viper
(D. russelli russelli) by gel-filtration chromatography on a Superdex
G-75 column, yielding eight major protein peaks (Fig. 1A). All of
the fractions (RV1 to RV8) were assayed for antibacterial activities,
of which RV5 showed significant antibacterial and PLA2 activity
versus RV4. The active fraction RV5 was further fractionated by
reverse phase (RP) chromatography on Sepharose (C18 column),
and resolved into four further fractions, namely RV-F1 to RV-F4
(Fig. 1B). The most active antibacterial fraction (RV-F4) was applied
to Sepharose C18 and C8 reverse phase columns and resolved into
two major purified proteins (Fig. 1C and D), subsequently desig-
nated as ‘‘Viperatoxins” VipTx-I and VipTx-II. The VipTx-II showed
more phospholipase A2 enzymatic activity than the VipTx-I. How-
ever, the protein purity was assessed by mass spec MALDI-TOF/MS
analysis showing the actual mass of VipTx-I (13669.93 daltons)
and VipTx-II (13869.05 daltons) (Fig. 1E and F). Protein purity
was assessed by SDS–PAGE, and molecular weight was estimated
to be approximately 15 kDa (Fig. 1G).
3.2. Phospholipase A2 enzyme activity
Phospholipase A2 (PLA2) enzyme was known to be a major com-
ponent of snake venoms showed important toxic and pharmaco-
logical effects. In this study, eight PLA2 enzyme fractions were
isolated from the crude venom such as RV1–RV8, of which fraction
RV5 was displayed higher enzyme activity/bactericidal potency
further purified by revere-phase chromatography (C18 column)
resolved into four fractions (RV-F1–RV-F4). Similarly, enzymati-
cally the most active fraction (RV-F4) was separated by C8 columns
and yielded VipTx-I/VipTx-II proteins. Fascinatingly, there was not
only a higher level of PLA2 enzymatic activity but also high
proteins levels of VipTx-II determined in this assay system
(Fig. S1 A and B).
3.3. Analysis of sequencing
The N-terminal amino acid (AA) residues of VipTx-I and VipTx-II
were sequenced, and compared with those found in the expert pro-
tein analysis system (ExPASY) proteomics database using a basic
local alignment search tool (BLAST) search alignment with several
types of snake venom PLA2s (Table. 1). The AA sequences were
matched exactly with the available sequences and its protein
masses varied from the existing snake venom PLA2s. The sequence
comparison shows that VipTx-II shares greatest sequence identity
(60–86%) with a PLA2 from other vipers, and a high degree of
sequence homology exists with the group RV-VIIIA PLA2s. In
particular, the N-terminal residues of VipTx-II matched with exist-
ing PLA2s, but slight modification of one or two new AA residues
found in the sequences are most likely due to post translational
modifications. The VipTx-II also shared much sequence homology
with the Asp-49 enzymes from several species. The BLAST search
Fig. 1. (A) High performance liquid chromatography (HPLC) profiles of D. russellii russellii crude venom from a Superdex G-75 column, (B) fraction RV5 further separated by
reverse-phase (RP)-HPLC spectrum of Sepharose C18 (RV-F1 to RV-F3) and (C and D) the most active fraction RV-F4 was further purified by C8 column and produced into two
pure proteins namely Viperatoxin (VipTx-I and VipTx-II), (E and F) molecular weight of proteins were analyzed by MALDI-TOF/MS, (G) protein profile determined by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE), lanes indicates: RV-CV Russell’s viper crude venom (1-4), lane (5-7) RP-HPLC fractions from C18 column,
the homogeneity or purity of lane (8) VipTx-II, lane (9) VipTx-I (20 lg of protein loaded per lane) was performed by SDS–PAGE respectively.
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dae. The N-terminal sequences (VipTx-II) were 91% identical to sp|
P86368|PA23_DABRR (showing 5th in the alignment). These basic
amino acids and hydrophobicity are essential for enhanced antimi-
crobial activity. Also, to the best of our knowledge, this is the first
detailed report on the antimicrobial activity of Indian viper venom
proteins along with their unique mechanisms of action.3.4. In vitro antimicrobial activity
Purified proteins (VipTx-I and VipTx-II) were tested for their
antibacterial properties against Gram-positive and Gram-negative
bacteria at a 100 lg/ml concentration. The enzyme exhibited broad
spectrum activity against a wide range of pathogenic organisms.
The VipTx-II enzyme showed very strong antimicrobial action
Table 1
Multiple sequence alignments for the N-terminal sequences of VipTx-I and VipTx-II phospholipase A2 (PLA2) from the Daboia russelli russelliwas compared with existing
snake venom basic phospholipase A2 sp|P59071|PA28_DABRR-VRV-PL-VIIIA of Daboia russelii (Russel’s viper), tr|D0VX11|D0VX11_DABRP-PLA2 VRV-PL-VIIIA (Daboia
russellii pulchella), tr|B3RFI8|B3RFI8_9SAUR-PLA2 (Daboia russellii limitis), tr|A8CG84|A8CG84_DABRU-basic PLA2 Drk-b2 (svPLA2) of Daboia russelii (Russel’s viper or
Vipera russelii), sp|P86368|PA23_DABRR-basic PLA2 of Daboia russelii (Russel’s viper), sp|P84674|PA25_DABRR-basic PLA2 VRV-PL-V of Daboia russelii (Russel’s viper), sp|
P14424|PA2B_VIPAA- neutral PLA2 agkistrodotoxin ATX) of Agkistrodon halys or Gloydius halys (Chinese water mocassin), sp|P00626|PA2A_VIPAA-PLA2, ammodytoxin A
[ATXA]of Vipera ammodytes ammodytes (Western sand viper) PLA2, sp|P11407|PA2C_VIPAA-ammodytoxin C [ATXC] of Vipera ammodytes ammodytes (Western sand
viper), sp|P59171|PA25_ECHOC-acidic PLA2 of Echis ocellatus (Ocellated saw-scaled viper), basic PLA2 myotoxin III (Bothrops asper), sp|P20474|PA21_BOTAS-basic
myotoxic PLA2 bothropstoxin-2 (BthTX-II) of Bothrops jararacussu (Jararacussu), sp|P45881|PA2B2_BOTJR-and sp|P86974|PA2D_BOTLC-basic PLA2 blD-PLA2) of Bothrops
leucurus (White-tailed lancehead).
Accession No N-terminal        Ca2+ -loob      Active site     β-wing     
1       10        20       30        40         50         60          70         80
(1) VipTx-I SLLGFGCMILEETGVMIELEKNCNQHPE----------------------------------------------------------
(2) VipTx-II   SLLEFGMMILEETGKLAVPFYSKYGLYCGCGGK-TPDD------------------------------------------------
sp|P59071|PA28_DABRR        SLLEFGKMILEETGKLAIPSYSSYGCYCGWGGKGTPKDATDRC-CFVHDC-CYGNLPDCNPKSDRYKYKRVNGAIVCEKGTSCENR
tr|D0VX11|D0VX11_DABRP      SLLEFGKMILEETGKLAIPSYSSYGCYCGWGGKGTPKDATDRC-CFVHDC-CYGNLPDCNPKSDRYKYKRVNGAIVCEKGTSCENR
tr|B3RFI8|B3RFI8_9SAUR      SLLEFGKMILEETGKLAIPSYSSYGCYCGWGGKGTPKDATDRC-CFVHDC-CYGNLPDCNPKSDRYKYKRVNGAIVCEKGTSCENR
tr|A8CG84|A8CG84_DABRU      SLLEFGKMILEETGKLAIPSYSSYGCYCGWGGKGTPKDATDRC-CFVHDC-CYGNLPDCNPKSDRYKYKRVNGAIVCEKGTSCENR
sp|P86368|PA23_DABRR        SLLEFGMMILEETGKLAVPFYSSYGCYCGWGGKATPKDATDRC-CFVHDC-CYGNLPDCNPKSDRYKYKRVNGAIVCEQGTSCENR
sp|P84674|PA25_DABRR        SLLEFGMMILEETGKLAVPFYSSYGCYCGWGGKGTPKDATDRC-CFVHDC-CYGNLPDCTPKPDRYKYKRVNGAIVCEQGTSCENR
sp|P14424|PA2B_VIPAA        SLLEFGMMILGETGKNPLTSYSFYGCYCGVGGKGTPKDATDRC-CFVHDC-CYGNLPDCSPKTDRYKYHRENGAIVCGKGTSCENR
sp|P00626|PA2A_VIPAA        SLLEFGMMILGETGKNPLTSYSFYGCYCGVGGKGTPKDATDRC-CFVHDC-CYGNLPDCSPKTDRYKYHRENGAIVCGKGTSCENR
sp|P11407|PA2C_VIPAA        SLLEFGMMILGETGKNPLTSYSFYGCYCGVGGKGTPKDATDRC-CFVHDC-CYGNLPDCSPKTDRYKYHRENGAIVCGKGTSCENR
sp|P59171|PA25_ECHOC        SVIEFGTMIIEETGRSPFPFYTSYGCYCGLGGKGKPKDDTDRC-CFVHDC-CYGSMPDCSPKTDIYRYHRENGEIICESGTSCEKR
sp|P20474|PA21_BOTAS        SLIEFAKMILEETKRLPFPYYTTYGCYCGWGGQGQPKDATDRC-CFVHDC-CYGKLSNCKPKTDRYSYSRKSGVIICGEGTPCEKQ
sp|P45881|PA2B2_BOTJR       DLWQFGQMILKETGKLPFPYYTTYGCYCGWGGQGQPKDATDRC-CFVHDC-CYGKLTNCKPKTDRYSYSRENGVIICGEGTPCEKQ
sp|P86974|PA2D_BOTLC        DLWQFGQMILKETGKLPFPYYTTYGCYCGWGGQGQPKDATDRC-CFVHDC-CYGKLTNCKPKTDRYSYSRENGVIICGEGTPCEKQ
.: :*. **: ** : ... *: ****** **:.*** *************.:.:*.**.* * * * .* *:* .**.**::
Accession No α-Helix Mass Homology (%) Residues
90       100      110       121
(1) VipTx-I -------------------------------------------------
(2) VipTx-II   -------------------------------------------------
sp|P59071|PA28_DABRR        ICECDKAAAICFRQNLNTYSKKYMLYPDFLCKGE-LKC-----------
tr|D0VX11|D0VX11_DABRP      ICECDKAAAICFRQNLNTYSKKYMLYPDFLCKGE-LKC-----------
tr|B3RFI8|B3RFI8_9SAUR      ICECDKAAAICFRQNLNTYSKKYMLYPDFLCKGE-LKC-----------
tr|A8CG84|A8CG84_DABRU      ICECDKAAAICFRQNLNTYSKKYMLYPDFLCKGE-LRC-----------
sp|P86368|PA23_DABRR        ICECDKAAAICFRRNLNTYSKIYMLYPDFLCKGE-LKC-----------
sp|P84674|PA25_DABRR        ICECDKAAAICFTKNLNTYSKIYMLYPDFLCKGE-LKC-----------
sp|P14424|PA2B_VIPAA        ICECDRAAAICFRKNLKTYNHIYMYYPDFLCKKESEKC-----------
sp|P00626|PA2A_VIPAA        ICECDRAAAICFRKNLKTYNYIYRNYPDFLCKKESEKC-----------
sp|P11407|PA2C_VIPAA        ICECDRAAAICFRKNLKTYNYIYRNYPDILCKEESEKC-----------
sp|P59171|PA25_ECHOC        ICECDKAAAVCFRENLKTYKNKYMVYPDSLCKEESEKC-----------
sp|P20474|PA21_BOTAS        ICECDKAAAVCFRENLRTYKKRYMAYPDLLCKKPAEKC-----------
sp|P45881|PA2B2_BOTJR       ICECDKAAAVCFRENLRTYKKRYMAYPDVLCKKPAEKC-----------
sp|P86974|PA2D_BOTLC        ICECDKAAAVCFRENLRTYKXXYMAYPDVLCKKPAEKC-----------
*****:***:** .**.**.  *  *** *** .
13869
13669
13611
13611
15353
15381
13687
15587
15529
15531
15498
15705
15751
15765
13933
86
85
82
82
82
81
78
76
69
69
68
62
60
60
60
28
35
121
121
137
137
121
121
138
138
138
138
138
138
121
The ExPasy tools BLAST used for the CLUSTAL W (1.82) multiple sequence alignment of viper PLA2s (phosphatidylcholine 2-acylhydrolase).
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and P. mirabilis (Fig. 2A and B). The most promising activity of
VipTx-II was compared with standard antibiotics (i.e. Ceftazidime,
Chloramphenicol, Penicillin, Streptomycin, and Vancomycin). The
inhibitory potential of VipTx-II was equal to that of standard
antibiotics like Streptomycin, Chloramphenicol and Ceftazidime.
However, VipTx-I exerted a very weak antimicrobial effect against
all the tested bacteria. Particularly it’s devoid of activity against P.
aeruginosa. However, this VipTx-II protein displayed the most
potent antibacterial activity compared to that of the VipTx-I pro-
tein. Similarly, the antimicrobial activity of VipTx-II prompted us
to conduct a further testing of MIC determinations by a broth dilu-
tion method.
3.4.1. Dose-dependent antimicrobial activity
Antibacterial susceptibility of the most effective protein
(VipTx-II) was further assayed against multi-drug resistant
(MDR) B. pseudomallei (strain of KHW) and S. aureus. The inhibitory
potential of VipTx-II was equal against both types of bacteria;
however, this protein was slightly more effective in controlling
the growth of B. pseudomallei at 10 lg/ml (Fig. 2C).
3.4.2. Minimum inhibitory concentrations (MICs)
The MICs of proteins (VipTx-I and VipTx-II) were determined by
broth-dilution assay with initial sample concentrations of 100, 50,
25, 12.5, 6.25, 3.125 and 1.56 lg/ml tested against Gram-positive
and Gram-negative strains, including B. pseudomallei (TES &
KHW). The MIC values are expressed as the lowest concentrationthat caused 100% bacterial growth inhibition. The VipTx-II exhib-
ited marked activity against B. pseudomallei KHW & TES (MICs of
6.25 lg/ml), S. aureus, (MICs 6.25 lg/ml), P. mirabilis (MICs of
12.5 lg/ml), P. vulgaris (MICs of 25 lg/ml), whereas E. coli, E. aero-
genes and P. aeruginosa showed weaker inhibitory MIC effects at all
dilutions (100–1.56 lg/ml) shown in Fig. 3A–H. Interestingly,
VipTx-II exhibited significant inhibition at the lowest dilution
against B. pseudomallei and S. aureus (MIC of 6.125 lg/ml). The bac-
tericidal (killing) potential of proteins was further quantified by a
TS and MH broth dilution method (100–1.56 lg/ml) as shown in
Table 2. The MBCs result revealed that VipTx-II exerted most sig-
nificant inhibition against KHW strains of B. pseudomallei and S.
aureus at the lowest dilutions (MBC 6.125 lg/ml) versus bacterial
control. The VipTx-I only weakly killed multi-drug resistant strains
of B. pseudomallei at all tested concentrations.
3.4.3. Mechanisms of action for VipTx-II
Smooth membrane structure was clearly evident in control
bacteria without treatment, B. pseudomallei (KHW) treated with
VipTx-II resulted in numerous mushroom-shaped blebs, thickening
irregular shapes and retraction of cytoplasm, while bacteria
appeared to be losing cell contents particularly at the division
septa after 24 h (Fig. 4A and B). Particularly after the treatment
of VipTx-II with Gram-positive (S. aureus), while fibrous and pre-
sumably cell contents (granular material) appeared to exude from
the damaged membranes (Fig. 4C–F) and the inner membrane
was difficult to discern. Bacteria treated with VipTx-II also
lost of the membrane structure and the formed of blebs in
Fig. 2. In vitro antimicrobial activity against Gram-positive and Gram-negative bacterial cells were determined by standard procedure. (A) The VipTx-I protein displayed less
activity against tested bacteria. (B) The VipTx-II protein showed most potent action against S. aureus and B. pseudomallei among the tested bacteria, the activity or inhibition
zones were compared with a antibiotic. The activity of VipTx-II protein more or less equal when compared to that of commercial antibiotic. (C) The VipTx-II protein showed
most potent action against S. aureus and B. pseudomallei (KHW & TES) and S. aureus among the tested bacteria, the activity or inhibition zones were compared with a variety of
antibiotics. (D) The active protein was further tested in a dose-dependent (100–0.01 lg/ml) manner against the most sensitive organisms. Results exhibited that the protein
exerted very strong bactericidal activity against B. pseudomallei (KHW) and S. aureus even at very low doses (10 lg/ml). Symbol denotes: Ec-Escherichia coli, Pv-Proteus
vulgaris, KHW-Burkholderia pseudomallei, Sa-Staphylococcus aureus, TES-Burkholderia pseudomallei, Pm-Proteus mirabilis, Ea-Enterobacter aerogenes, STR-Streptomycin,
CHL-Chloramphenicol, CF-Ceftazidime, PEN-Penicillin, VAN-Vancomycin.
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microscopy (Fig. 4G and H) than the control (ctrl). The ultra-
structural studies have proven the pore-forming action of
VipTx-II enzyme on bacteria. Generally, viper proteins induced
specific structural and morphological changes versus untreated
bacterial controls.3.5. Morphological and cellular toxicity
Cytotoxicity results indicated that VipTx-II did not affect the
cell viability up to a concentration of 1000 lg/ml. Human macro-
phages (THP-1) were not affected particularly at 625 lg/ml in a
cytotoxicity assay. Exposure to VipTx-II revealed minimal
Fig. 3. The MICs values were determined by a modified micro-broth dilution assay using VipTx-II against Gram-negative and Gram-positive bacteria. (A–H) VipTx-II inhibits
S. aureus and B. pseudomallei in a dose-dependent fashion and less number of colonies was observed. The activity of VipTx-II was 10-fold greater against S. aureus and
B. pseudomallei, each breaking point represents the mean of triplicate samples. VipTx-II inhibits S. aureus (MICs 6.125 lg/ml), B. pseudomallei KHW & TES (MICs 6.125 lg/ml),
Proteus mirabilis (MICs 12.5 lg/ml) and Proteus vulgaris (MICs 25 lg/ml) more effectively versus P. aeruginosa, Escherichia coli and Enterobacter aerogenes.
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Table 2
Minimum bactericidal concentrations (MBCs) of viperatoxins isolated from the Indian
Russell’s viper snake venom (Daboia russellii russellii).a
Bacteria MBCsa
VipTx-I (lg/ml) VipTx-II (lg/ml)
Escherichia coli 100 100
Enterobacter aerogenes 100 100
Proteus vulgaris 50 12.5
Proteus mirabilis 50 12.5
Pseudomonas aeruginosa 100 100
Staphylococcus aureus 50 6.25
Burkholderia pseudomallei (strain KHW) 100 6.25
Burkholderia pseudomallei (strain TES) 100 6.25
a The MBC values were determined by a modified micro-broth dilution assay
using snake venom proteins (100, 50, 25, 12.5, 6.25, 3.125 lg/ml). Antimicrobial
activity of viperatoxin (VipTx-I and VipTx-II) was determined by MBCs in a solution
killing assay against Gram-negative and Gram-positive bacteria.
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VipTx-II gradually decreased THP-1 cell proliferation after treat-
ment with enzymes (Fig. 5A and B). However, cell survival
decreased with increasing concentrations of VipTx-I from 39 to
10,000 lg/ml and EC50 1250 lg/ml (Fig. 5C and D). The morpholog-Fig. 4. The mechanisms of action of antimicrobial protein was postulated by SEM examin
pore formation (blebs), disintegration of bacterial membranes heavily and release of
(S. aureus). (G and H) Transmission electron microscopic studies additionally damaged
denotes: pf-pore formation, rs-rough surface, md- membrane damage, is-irregular shapical changes of the cells revealed that membrane disruption, lysis
and significant cell death was evident at a 2500 lg/ml concentra-
tion of VipTx-I in a time and dose dependent (24 and 48 h) manner.
Sixty percent of the THP-1 cells were inhibited by the exposure of
VipTx-I after 48 h than in the control. However, the cytolytic levels
were at higher concentrations up to 2500 lg/ml (Fig. 5E–H).
3.6. LDH assay
The LDH results revealed that THP-1 cells exposed to VipTx-II
were not affected up to 1250 lg/ml concentrations (Fig. 6A
and B). Significant cell death is evident at higher concentration
(2500 lg/ml) in a dose and time-dependent manner (24 and
48 h), as a result there is more LDH release into the media.
However, the cell proliferation was not affected especially at the
optimal dose of VipTx-II (EC501250 lg/m1) than the VipTx-II
(Fig. 6C and D). The optimum dose that inhibited bacterial prolifer-
ation did not affect the THP-1cells.
4. Discussion
Bacterial resistance is a significant problem for treating infec-
tions, and thus there is a keen interest in research directedation. (A) Control – clear architecture, (B–F) The protein (VipTx-II) exerted excellent
cellular contents after exposure at 6.25 lg/ml (B. pseudomallei) and 12.25 lg/ml
of cell wall and loss of cellular content after 24 h treatment of VipTx-II. Symbol
es, ns-normal surface, ctrl-control.
Fig. 5. (A and B) Evaluation of MTT-based cytotoxicity of proteins incubated with human cells (THP-1) and various concentrations of VipTx-II after 24 h and 48 h
incubation. Control (Ctrl) cells without treatment used as a control. (C and D) Cytotoxicity of protein of VipTx-I on THP-1cells were incubated with the different
concentrations (10,000–39 lg/ml), VipTx-I showed severe reduction of cell proliferation and more toxicity up to 1250 lg/ml than the VipTx-II up to only 5000 lg/ml. Light
micrograph showing the normal architecture of THP-1 cells, (E) THP-1 cells without treatment served as a control, (F–H) cells treated with 2500, 5000 and 10,000 lg/ml
concentrations of protein VipTx-II caused morphological changes after exposure (Magnification 20).
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Fig. 6. Cell death and cell lysis were determined by LDH activity released from the cytosol of damaged cells into the supernatant after exposure of proteins. (A–D) The VipTx-II
protein did not lyse THP-1 cells exposed up to 1250 lg/ml doses, whereas the VipTx-I protein was induced higher percentage of cell death and more release of LDH in the
culture supernatant.
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venomous animals contain a variety of venom proteins which
participate in both digestion of prey and venom toxicity. Viperi-
dae snake venoms represent a source of important bioactive
molecules that have led to the development of diverse new drugs
in clinical scenario. In this study, novel snake venom proteins
were purified and designated as ‘‘Viperatoxin” (VipTx-I and
VipTx-II) from the Indian Russell’s viper (D. russelli russelli). The
N-terminal amino acid residues of VipTx-I and VipTx-II were
sequenced, and compared with existing sequences in the ExPASY
proteomics database using BLAST.
The sequence comparison shows that VipTx-II matched 60–86%
homology with existing snake venom phospholipase A2s (svPLA2s).
The molecular weight of VipTx-I and VipTX-II slightly differs with
the previously reported protein masses from known PLA2s. Our
results corroborate with the N-terminal sequences of B. neuwiedi
pauloensis showed important homology with Asp49 basic myotoxic
PLA2s from other snake venoms [44]. Whereas, Lys49 PLA2
(myotoxin I) elucidated from B. atrox venom displays very high
level of homology with other Lys49 PLA2s, although its primary
and three-dimensional structure show some difference in the
C-terminal region [45]. Generally, characterized svPLA2s have a
conserved fold with seven disulfide bridges and a histidine at the
catalytic site, with calcium (Ca2+) bound at the active site
[11,28,46]. The Russell’s viper svPLA2 structure also contains a
Trp-31-containing loop (residues 25-34), b-wing consisting of
double-stranded anti-parallel b-strands (residues 74-85) and
C-terminal region 9 (residues 119-133). The crystal structures ofcomplexes with transition analogs provide insights into the poten-
tial catalytic mechanisms with the presence of fatty acid in the
hydrophobic channel [47].
Several recent studies have shown that antimicrobial proteins
and peptides are produced by many living organisms and repre-
sent a novel class of antibiotics to treat infectious diseases [8].
Examples include crotamine, a myotoxin from venom of the South
American rattlesnake, which is structurally related to beta-
defensins. The later are antimicrobial peptides found in vertebrate
animals [13], peptides from Naja naja venom [48], and a venom
protein from the inland taipan which all exhibit antimicrobial
activity. Previous studies have shown that the naturally occurring
proteins display antimicrobial activity [12]. Remarkably, a group
of Lys-49 PLA2s homologues present in snake venoms [19], are
bactericidal even though they lack enzymatic activity. Another
study shows that myotoxic PLA2s are bactericidal against E. coli
and S. aureus [20].
In this study, VipTx-II exerted the most potent action against a
multi-drug resistant strain (KHW) of B. pseudomallei as compared
to the less resistant TES strains. The inhibitory potential of
VipTx-II was quite equivalent to that of standard antibiotics such
as streptomycin, chloramphenicol, ceftazidime and vancomycin
versus VipTx-I. Further, we tested the antibacterial properties of
VipTx-II and found that it killed several strains of Gram-positive
and Gram-negative bacteria, with doses ranging from
(100–0.01 lg/ml). The dose-dependant assay revealed bacterial
killing by viper protein within 24 h and reached the maximum
(75%) activity at a 10 lg/ml concentration. Our earlier study
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bactericidal effects against B. pseudomallei [49]. Our study, in
contrast with the EcTx-I protein from the venoms of Saw-scaled
viper species, demonstrated significant bactericidal inhibition of
multi-drug resistance (MDR) B. pseudomallei (KHW) and
E. aerogenes previously [38]. VipTx-II exerted the most significant
inhibition against B. pseudomallei KHW strains even at the lowest
dilutions (MICs 6.25 lg/ml). Interestingly, the VipTx-II protein
showed very significant inhibitory effects against S. aureus,
P. vulgaris and P. mirabilis even at 12.25 lg/ml doses (in a dose-
dependent manner). Whereas, recently reported studies show that
a basic protein of VRV-PL-V from Daboia russelli pulchella (venom
PLA2 fraction V) effectively inhibits Gram-positive bacteria such
as S. aureus and Bacillus subtilis at MICs 13-24 lg/ml versus
Gram-negative E. coli, Vibrio cholerae, Klebsiella pneumoniae and
Salmonella paratyphi [50]. Similarly the PLA2 fraction VIIIA of
D. russelli pulchella (VRV-PL-VIIIa) also controls the growth of bac-
teria at 11–19 lg/ml doses [51], BnpTX-1/II is a basic myotoxic
PLA2s obtained from B. neuwiedi pauloensis snake venom, BnpTX-
1 showed the neurotoxic as well as antibacterial activity on
E. coli and S. aureus [44]. The Lys49 phospholipase A2 (PLA2) of
Bothrops atrox (myotoxin I) displays only a weak antibacterial
activity on bacteria [45], whereas synthetic peptide derived from
the Lys49 PLA2 of C-terminal segment of B. asper (myotoxin II)
and tryptophan (Tyr–Trp) substitution enhances antimicrobial
potency on Gram-negative (Salmonella typhimurium) and Gram-
positive bacteria (S. aureus), with low cytotoxicity on skeletal
muscle cells, C2C12 myoblasts [22]. Cardiotoxin 3 (CTX3) isolated
from Naja naja atra (Taiwan cobra) exerts the most potent
inhibitory effects against S. aureus than E. coli [52]. However, the
VipTx-II displays the most potent inhibitory effects against
B. pseudomallei KHW (MICs 6.25 lg/ml) as well as S. aureus,
P. vulgaris and P. mirabilis (MICs 12.25 lg/ml) at very low concen-
trations compared to the existing PLA2s.
We found novel bactericidal mechanisms attributed to viper
proteins (VipTx-I and VipTx-II) that induced pore formation on
clinical isolates such as MDR B. pseudomallei (KHW strain). There
were cellular changes that include membrane disintegration. Our
study corroborate with membrane damage elicited by the binding
of protein to the lipid membrane [53]. Recently, there have been
suggestions that transmembrane pore formation is not the only
mechanism of microbial killing [54]. Several earlier observations
indicate that translocated protein or peptides can alter cytoplasmic
membrane septum formation, inhibit cell-wall, nucleic-acid and
protein synthesis or inhibit enzymatic activity [54]. Previously
study of the mechanisms was clearly evidenced that the antimicro-
bial protein as well as peptides induced killing of microorganisms
by severely damaging membrane and formation of pores on
invading pathogens [38]. Therefore, sPLA2 is implicated in the lipid
digestion as a host defence mechanism including the observed
antibacterial activities [55].
Enzymatically-independent bactericidal effects of PLA2 has
been demonstrated and mapped to a specific membrane-
damaging protein site [20]. A number of Trp substituted peptides
derived from svPLA2 can increase microbicidal potency against
both Gram-negative and Gram-positive bacteria [25]. Previous
studies also show that the interaction of this peptide with the
lipopolysaccharide (LPS) and lipid A or lipoteichoic acid (LA) relies
on a membrane-permeabilizing mechanism to exert its bacterici-
dal effects [20]. In addition to Trp, Pro and Arg residues are also
important in membrane disruption and/or cell entry. Thus these
later Pro and Arg residues are an attractive template for designing
novel antimicrobial peptides effective against a broad spectrum of
microorganisms [56]. In addition, it has been reported that the
insertion of positively-charged amino acids can result in big varia-
tions and high antibiotic activity. These peptides also significantlyreduce hemolysis and cytotoxicity that correlate with decreased
permeabilization of the zwitterionic phosphatidylcholine mem-
brane, the major component of outer leaflets from red blood cells
[56].
Several proteins and polypeptides of reptiles have common
cytolytic properties, and these cytolysins provide an offensive
armament for the animal defense. In this study, cell survival
decreased with the increasing concentrations of viper protein
(VipTx-I) at 39–10,000 lg/ml than VipTx-II. However, the enzyme
(VipTx-II) has low level of toxicity for eukaryotic cells at higher
concentrations. The morphological changes in THP-1 cells show
membrane disruption, lysis and significant cell death apparent at
2500 lg/ml with VipTx-I in a time-dependent manner (24 and
48 h). Although, 60% of the cells were killed by the VipTx-I after
48 h, but the observed cytolytic effects were very high at higher
protein concentrations (1250 lg/ml). This may be due to the mech-
anism for clearing free fatty acids that is toxic to the cell for retain-
ing cellular energy reserve. Those fatty acids might be acylated by
intracellular located enzymes to membrane-bound proteins. Acyla-
tion of these proteins can be potentially one of the mechanisms for
disrupting membrane integrity and cellular signaling [57].
4.1. Mechanisms of actions
The antimicrobial potency of snake venom is largely unex-
plored. Naturally occurring snake venom proteins and peptides
possess highly potent antimicrobial activity against B. pseudomallei
[58]. A family of sPLA2 comprised of low molecular weight
(13 kDa), disulfide-linked proteins [59] depend on Ca2+ for enzy-
matic activity and play an important role in innate immunity and
killing of bacteria [60]. Antimicrobial proteins/peptides generally
kill bacteria by permeabilizing and or disrupting their membranes
[61]. The molecular basis for the activity and selectivity of these
peptides has been studied in model membranes [61]. Cationic
antimicrobial peptides interact preferentially with acidic lipids
that are chiefly abundant and found in bacteria [38]. However,
the basic proteins manifest strong amphiphilic properties on their
molecular surface. For example, apolar tips of loops I-III form a
hydrophobic zone flanked by a positively-charged Lys and Arg resi-
dues. Another membrane model study demonstrates that the
hydrophobic bottom represents a principal membrane-binding
motif for protein [62]. In addition, the structural defects in lipid
bilayers induced by protein binding to the membrane can lead to
the formation of pores [63]. The explanations above provide a basis
for the major differences in cell specificity by various antimicrobial
peptides/proteins. Interaction of peptides with bilayers alters the
organization of the membranes and makes them more permeable
to ions [64]. Overall, it is not only the nature of a protein and
peptide, but also various characteristics of the cell membrane
and metabolic state of the target cell, that ultimately determine
the mechanism of antimicrobial activity.
In conclusion, we report for the first time a novel bactericidal
protein, VipTx-II, from the crude venom of a Indian Russell’s viper.
These protein possessed powerful antibacterial properties against
Gram-positive and Gram-negative bacteria, in which VipTx-II was
more effective against S. aureus and B. pseudomallei (KHW) than
VipTx-I. Thus, the studies provide novel insights into the molecular
mechanisms of action involving membrane damage and pore
formation induced by viper VipTx-II. Furthermore, VipTx-II is not
cytotoxic on human macrophages (THP-1) in comparison to
VipTx-I. Further studies should help to completely solve the struc-
ture of these proteins that can be very useful to elucidate their
detailed mechanisms of action in vivo. Thus, the observed antimi-
crobial activities of viper venom proteins/derived peptides could
be further useful for developing potential antimicrobial candidates
against drug-resistant Gram-negative and Gram positive bacteria.
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